These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 29966356

  • 1. HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.
    Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B, Campadelli-Fiume G.
    Viruses; 2018 Jun 30; 10(7):. PubMed ID: 29966356
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.
    Leoni V, Petrovic B, Gianni T, Gatta V, Campadelli-Fiume G.
    J Virol; 2018 Mar 15; 92(6):. PubMed ID: 29263255
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
    Campadelli-Fiume G, Petrovic B, Leoni V, Gianni T, Avitabile E, Casiraghi C, Gatta V.
    Viruses; 2016 Feb 26; 8(3):63. PubMed ID: 26927159
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.
    Menotti L, Nicoletti G, Gatta V, Croci S, Landuzzi L, De Giovanni C, Nanni P, Lollini PL, Campadelli-Fiume G.
    Proc Natl Acad Sci U S A; 2009 Jun 02; 106(22):9039-44. PubMed ID: 19458262
    [Abstract] [Full Text] [Related]

  • 10. Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins.
    Petrovic B, Gianni T, Gatta V, Campadelli-Fiume G.
    PLoS Pathog; 2017 Apr 02; 13(4):e1006352. PubMed ID: 28423057
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
    Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G.
    J Virol; 2008 Oct 02; 82(20):10153-61. PubMed ID: 18684832
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells.
    Hall BL, Leronni D, Miyagawa Y, Goins WF, Glorioso JC, Cohen JB.
    Int J Mol Sci; 2020 Nov 21; 21(22):. PubMed ID: 33233403
    [Abstract] [Full Text] [Related]

  • 19. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.
    Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, Zaghini A, Nanni P, Lollini PL, Casiraghi C, Campadelli-Fiume G.
    PLoS Pathog; 2018 Aug 21; 14(8):e1007209. PubMed ID: 30080893
    [Abstract] [Full Text] [Related]

  • 20. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
    Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall'Ora M, Grosso V, Rossi M, Alviano F, Bonsi L, Nanni P, Lollini PL, Campadelli-Fiume G.
    Oncotarget; 2015 Oct 27; 6(33):34774-87. PubMed ID: 26430966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.